Michael Taylor brings over 25 years of experience in global credit markets, with a focus on special situations and capital formation. He has served as Partner at the Adi Dassler International Family Office in Nassau, Bahamas, and as Managing Director at Oppenheimer & Co., where he specialized in complex debt structuring and multijurisdictional transactions. Prior to that, he spent eight years at Stone & Youngberg as Managing Director of Institutional Fixed Income Trading and Alternative Investments. Michael began his career as a Bond Trader at Morgan Stanley.
A graduate of the London School of Economicswith a Bachelor of Science in Economics and International Relations, Michael has built a reputation for navigating complex financial environments and delivering innovative solutions. These skills will be integral to the growth of the HOPE clinic network. He joins NRx Pharmaceuticals as the Board Designee of Smith & Sauer, LLC, following the recently announced financing.
Board Observer
Anita Nunes, CEO and Co-Founder of Smith & Sauer, LLC, is an accomplished executive with more than 20 years of experience leading transformative growth across industries. She has driven investments in pioneering ventures, including Smith and Sauer’s recent $27 millioninvestment in Hope Therapeutics and NRx Pharmaceuticals, where her leadership is advancing mental health care and pharmaceutical innovation.
Anita has a strong background in artificial intelligence, where she has led global initiatives to integrate AI-driven solutions, enabling businesses to achieve operational excellence and adapt to dynamic market demands. Her extensive healthcare expertise includes work with industry leaders McKesson and Gilead, where she was instrumental in managing strategic initiatives and fostering innovation.
In addition to her work at Smith & Sauer, Anita is the Founder of Mocktail Nation, a health-conscious beverage brand, and Pluzze Consulting, where she has provided strategic guidance to empower entrepreneurs and investors. Her ability to align financial strategies with impactful outcomes has positioned her as a leader in purpose-driven investments, delivering long-term value to stakeholders and society. She has served on multiple Boards of Directors and is recognized for her extensive expertise in healthcare, technology, and pharmaceuticals.
Founder, Chairman & Chief Scientist; Co-CEO HOPE Therapeutics
Dr. Javitt has been a founder of seven successful healthcare IT and biopharma startups with public exits. He has additionally led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer. He was appointed to healthcare leadership roles under Presidents Reagan, George H.W. Bush, Clinton, and George W. Bush. In the latter role he was commissioned by President Bush to Chair the Health Committee of the President’s Information Technology Advisory Committee (PITAC) and to lead the development of Executive Order 13335, establishing the Office of the National Coordinator for Health IT. In the aftermath of 9/11, Dr. Javitt was appointed a Senior Fellow in the National Security Health Policy Center of the Potomac Institute for Policy Studies to focus on biosecurity preparedness and appointed by President Bush to the Office of the Undersecretary of Defense. He is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and Johns Hopkins School of Medicine. The Harvard Chan School awarded him the Alumnus of Merit award in 2016 and he continues to serve as Adjunct Professor of the Johns Hopkins School of Medicine. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and Pharmacoeconomics that have been cited by more than 29,000 scientists. In his role as Chief Scientist of NRx Pharmaceuticals he continues to lead NRx on Scientific matters to advance and expand our pipeline of lifesaving medicines.
Dr. McBride has led numerous national and international initiatives in neuroscience and its interface with information technology, national security, and medical technology/drug development within the federal government, three of which are now multi-billion dollar enterprises. Dr. McBride began his career as a medical scientist in Naval Aviation and ergonomics and served in eight nationally prominent laboratories, including the Defense Advanced Research Projects Agency (DARPA), Naval Aerospace Medical Research Lab, Naval Research Lab, the Office of Naval Research, and the Naval Medical Research Institute. Upon retiring as a highly decorated senior officer (O-6), he assumed leadership of the Potomac Institute for Policy Studies, where he continues to serve as President Emeritus. Following his ten-year term, he was recruited back to the National Defense University to lead the Center for Technology and National Security Policy, culminating his government career as a Senior Executive-4 (Civilian equivalent to Rear Admiral/Vice Admiral). Dr. McBride has served as an adviser to Cabinet Secretaries, US Congressional Committees, and to corporate C-Suite executives. His educational background includes formal enrollment at the University of Georgia, Naval Aerospace Medical Institute (flight surgeon school), the University of Southern California, the London School of Economics, and Harvard Business School, earning a Ph.D. in experimental psychology, four master’s degrees, and an additional postdoctoral education in aviation medicine, systems engineering science, and strategic disruption. He has published widely and was elected by faculty in 1999 to full professor. Dr. McBride has served at multiple universities in colleges of Arts & Sciences, Engineering, Public Policy, and Medicine. For the past 12 years, Dr. McBride has served as an adjunct Professor at Georgetown University School of Medicine and co-Director of Georgetown’s Regulatory Science Program.
Mr. Chaim Hurvitz has served as the Chief Executive Officer of CH Health since May 2011. He previously served as the President of Teva International Group at Teva Pharmaceutical Industries Ltd., from April 2002 to 2010 and was a Director and member of the senior management of Teva Pharmaceuticals Industries Ltd. He serves as the Chairman of Galmed Pharmaceuticals Ltd. and has been its Director since 2011. He has been a Director of TheraCoat Ltd. since October 2010. He is a member of the management of the Manufacturers Association of Israel and head of its pharmaceutical branch. Mr. Hurvitz holds a Bachelor of Arts degree in political science and economics from Tel Aviv University.
Dr. Glied, whose principal areas of research are in health policy reform and mental health care policy, was named Dean of New York University’s Robert F. Wagner Graduate School of Public Service in 2013. From 1989-2013, Dr. Glied was professor of health policy and management at Columbia University’s Mailman School of Public Health and served as chair of the department of health policy and management from 1998-2009. In 2010, Dr. Glied was confirmed by the U.S. Senate as Assistant Secretary for Planning and Evaluation at the Department of Health and Human Services, serving in that capacity from July 2010 through August 2012. She had previously served as senior economist for health care and labor market policy on the President’s Council of Economic Advisers in 1992-1993, under Presidents Bush and Clinton, and participated in the Clinton Health Care Task Force.
Audit Committee Chair
Mr. Flynn is a founding investor in NRx. He is an entrepreneur with more than 30 years of senior executive experience. He has provided leadership to numerous successful organizations and has served in a variety of roles, including CEO, COO, CFO and advisor. Pat currently serves as COO of Good Measures, Inc. He co-founded Predilytics, Inc., which was sold to Welltock, Inc. Previously, Pat served as COO and then as CEO of Health Dialog, which was sold to BUPA International. Pat continued with BUPA, opening its business in the GCC and China. Mr. Flynn began his career with Bank of America where he held several positions over the course of 15 years, including Vice President of World Banking and Vice President of Risk Management.
Mr. Gorovitz is a partner of the AHG Group. In addition to his 25 years of legal experience in complex commercial transactions, he has considerable involvement in early-stage biotechnology and health information technology companies.
